Seres therapeutics reports fourth quarter and full year 2021 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported fourth quarter and full year 2021 financial results and provided business updates. “the progress made throughout 2021 has set the stage for an exciting year ahead for seres, highlighted by the anticipated bla filing for ser-109 with the u.s. food and drug administration (fda) for recurrent c. difficile infection (rcdi) in mid-2022 which, if approved, we expect to
mcrb Ratings Summary
mcrb Quant Ranking